| __timestamp | ACADIA Pharmaceuticals Inc. | Novartis AG |
|---|---|---|
| Wednesday, January 1, 2014 | 32748000 | 14993000000 |
| Thursday, January 1, 2015 | 90804000 | 14247000000 |
| Friday, January 1, 2016 | 186456000 | 14192000000 |
| Sunday, January 1, 2017 | 255062000 | 14997000000 |
| Monday, January 1, 2018 | 265758000 | 16471000000 |
| Tuesday, January 1, 2019 | 325638000 | 14369000000 |
| Wednesday, January 1, 2020 | 388661000 | 14197000000 |
| Friday, January 1, 2021 | 396028000 | 14886000000 |
| Saturday, January 1, 2022 | 369090000 | 14253000000 |
| Sunday, January 1, 2023 | 402466000 | 12489000000 |
| Monday, January 1, 2024 | 12566000000 |
In pursuit of knowledge
In the world of pharmaceuticals, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Novartis AG and ACADIA Pharmaceuticals Inc. have showcased contrasting SG&A spending patterns. Novartis, a global giant, consistently allocated around 14% of its revenue to SG&A, peaking in 2018. In contrast, ACADIA, a smaller player, saw its SG&A expenses grow by over 1,100% from 2014 to 2023, reflecting its aggressive expansion strategy. Notably, in 2023, ACADIA's SG&A expenses reached their highest, while Novartis experienced a decline. This divergence highlights the different growth stages and market strategies of these companies. As the pharmaceutical landscape evolves, understanding these spending patterns offers valuable insights into corporate priorities and market positioning.
Breaking Down SG&A Expenses: Novo Nordisk A/S vs ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Novartis AG
Operational Costs Compared: SG&A Analysis of Novartis AG and Alnylam Pharmaceuticals, Inc.
Novartis AG and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Novartis AG or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Novartis AG and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Novartis AG and BioCryst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Pharming Group N.V. vs ACADIA Pharmaceuticals Inc.
ADMA Biologics, Inc. or ACADIA Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Perrigo Company plc or ACADIA Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: ACADIA Pharmaceuticals Inc. vs Iovance Biotherapeutics, Inc.
Cost Management Insights: SG&A Expenses for ACADIA Pharmaceuticals Inc. and Geron Corporation